Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Endocrinol Diabetes Nutr (Engl Ed) ; 70(2): 80-87, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36890019

ABSTRACT

INTRODUCTION: The evolution of the incidence of type 1 diabetes (T1D) in all groups is controversial. Our objective is to study the incidence from 2009 to 2020, based on the Type 1 Diabetes Registry of Navarra, and to analyze the clinical presentation as diabetic ketoacidosis (DKA), and HbA1c at onset. MATERIALS AND METHODS: Descriptive study of all cases diagnosed as T1D and included in the Population Registry of T1D of Navarra in the period 1/1/2009 to 12/31/2020. Data are obtained from primary and secondary sources with an ascertainment rate of 96%. Incidence rates are expressed per 100,000 person-years of risk, by age group and sex. Likewise, a descriptive analysis of the HbA1c and DKA at diagnosis of each patient is performed. RESULTS: 627 new cases are registered, which represents an incidence of 8.1 (10 in men, 6.3 in women), without differences throughout the analyzed period. The group with the highest incidence is the 10-14 years old children (27.8), followed by that of 5-9 years old (20.6). The incidence in people older than 15 years is 5.8. Twenty six percent of patients present DKA at onset. The global mean of HbA1c is 11.6%, without changes throughout the studied period. CONCLUSIONS: The population registry of T1D of Navarra shows a stabilization in the incidence of T1D at all ages in the 2009-2020 period. The percentage of presentation as severe forms is high, even in adulthood.


Subject(s)
Diabetes Mellitus, Type 1 , Diabetic Ketoacidosis , Male , Child , Humans , Female , Adolescent , Child, Preschool , Diabetes Mellitus, Type 1/complications , Incidence , Glycated Hemoglobin , Diabetic Ketoacidosis/epidemiology
2.
J Cardiovasc Dev Dis ; 9(1)2022 Jan 13.
Article in English | MEDLINE | ID: mdl-35050235

ABSTRACT

(1) Background: Patients with schizophrenia have higher mortality, with cardiovascular diseases being the first cause of mortality. This study aims to estimate the excess risk of hospital admission for cardiovascular events in schizophrenic patients, adjusting for comorbidity and risk factors. (2) Methods: The APNA study is a dynamic prospective cohort of all residents in Navarra, Spain. A total of 505,889 people over 18 years old were followed for five years. The endpoint was hospital admissions for a cardiovascular event. Direct Acyclic Graphs (DAG) and Cox regression were used. (3) Results: Schizophrenic patients had a Hazard Ratio (HR) of 1.414 (95% CI 1.031-1.938) of hospital admission for a cardiovascular event after adjusting for age, sex, hypertension, type 2 diabetes, dyslipidemia, smoking, low income, obesity, antecedents of cardiovascular disease, and smoking. In non-adherent to antipsychotic treatment schizophrenia patients, the HR was 2.232 (95% CI 1.267-3.933). (4) Conclusions: Patients with schizophrenia have a higher risk of hospital admission for cardiovascular events than persons with the same risk factors without schizophrenia. Primary care nursing interventions should monitor these patients and reduce cardiovascular risk factors.

3.
J Clin Med ; 10(24)2021 Dec 14.
Article in English | MEDLINE | ID: mdl-34945149

ABSTRACT

Type 2 diabetes (T2D) is associated with increased cardiovascular morbidity, mortality, and hospital admissions. This study aimed to analyze how the differences in delivered care (variability of glycosylated hemoglobin (HbA1c) achieved targets) affect hospital admissions for cardiovascular events (CVEs) in T2D patients. Methods: We analyzed the electronic records in primary care health centers at Navarra (Spain) and hospital admission for CVEs. We followed 26,435 patients with T2D from 2012 to 2016. The variables collected were age, sex, health center, general practitioner practice (GPP), and income. The clinical variables were diagnosis of T2D, weight, height, body mass index (BMI), blood pressure (BP), HbA1c, low-density lipoprotein cholesterol (LDL-C), smoking, and antecedents of CVEs. We calculated, in each GPP practice, the proportion of patients with HbA1c ≥ 9. A non-hierarchical K-means cluster analysis classified GPPs into two clusters according to the level of compliance with HbA1C ≥ 9% control indicators. We used logistic and Cox regressions. Results: T2D patients had a higher probability of admission for CVEs when they belonged to a GPP in the worst control cluster of HbA1C ≥ 9% (HR = 1.151; 95% CI, 1.032-1.284).

4.
J Clin Med ; 10(13)2021 Jun 28.
Article in English | MEDLINE | ID: mdl-34203208

ABSTRACT

BACKGROUND: We analyzed the relationship between the prevalence of schizophrenia and the season of birth and gestation during a period of an influenza pandemic. METHODS: Cross-sectional analysis of a prospective population-based cohort of 470,942 adults. We fitted multivariant logistic regression models to determine whether the season of birth and birth in an influenza-pandemic year (1957, 1968, 1977) was associated with schizophrenia. RESULTS: 2077 subjects had been diagnosed with schizophrenia. Logistic regression identified a significantly greater prevalence of schizophrenia in men than in women (OR = 1.516, CI 95% = 1.388-1.665); in those born in the winter or spring than in those born in the summer or autumn (OR = 1.112, CI 95% = 1.020-1.212); and in those born in a period of an influenza pandemic (OR = 1.335, CI 95% = 1.199-1.486). The increase in risk was also significant when each influenza pandemic year was analyzed separately. However, neither month of birth nor season of birth, when each of the four were studied individually, were associated with a statistically significant increase in that risk. CONCLUSIONS: The winter-spring period and the influenza pandemics are independent risk factors for developing schizophrenia. This study contradicts many previous studies and thus revitalizes a locked debate in understanding the neurodevelopmental hypothesis of this disorder.

5.
Clin Endocrinol (Oxf) ; 89(3): 367-375, 2018 09.
Article in English | MEDLINE | ID: mdl-29893010

ABSTRACT

CONTEXT: To study the prevalence of thyroid dysfunction in a very large unselected population. OBJECTIVE: To determine the prevalence of abnormal thyroid function and evaluate potential modulatory factors. DESIGN AND SETTING: The Estudio de Atención Primaria de Navarra, The APNA Study, is a cross-sectional study conducted in northern Spain. It involved 303 883 people, of 20 years of age and older, who live in the Navarra region. Participants are covered by the public healthcare system and medical records are digitalized. MAIN OUTCOME MEASURES: The information was gathered from e-registered data regarding serum thyrotropin (TSH), thyroid hormones, thyroid antibody concentration and clinical context. Measurements were logged (demographic information and potential thyroid function modulatory factors). RESULTS: Serum TSH (mU/L) normal range was established at 0.7-4.28. At the time of the study, 87% of the Navarra population had a TSH level within the normal range. Mean serum TSH in euthyroid individuals was higher in women (2.15) than in men (1.96) (P < .001) and higher in the obese with body mass index (BMI) ≥30 kg/m2 (2.12) as compared to the non-obese BMI <30 kg/m2 (2.06) (P < .001). Mean TSH for the entire population was 1.9. The native Spanish population had statistically significantly lower TSH (1.87) than non-native Spanish (2.15) (P < .001). Additionally, we observed that serum TSH levels decreased with age and an increase in the prevalence of hypothyroidism in the elderly and among people with low-income levels. The prevalence of thyroid dysfunction in Navarra was 12.3%. The prevalence of hypothyroidism (or high TSH) in the population was 8.8% (13.3% in women, 4.2% in men), and the prevalence of hyperthyroidism (or low TSH) was 4.3% (5.6% in women, 3.0% in men). CONCLUSIONS: Nearly 15% of the general population suffers from biochemical thyroid dysfunction. The serum TSH level appears to be influenced by sex, BMI, age, ethnic origin and socio-economic status.


Subject(s)
Thyroid Diseases/epidemiology , Thyroid Gland/pathology , Body Mass Index , Cross-Sectional Studies , Female , Humans , Hypothyroidism/blood , Hypothyroidism/epidemiology , Male , Prevalence , Socioeconomic Factors , Thyroid Diseases/blood , Thyroid Hormones/blood , Thyrotropin/blood , Triiodothyronine/blood
6.
Prim Care Diabetes ; 12(1): 34-44, 2018 02.
Article in English | MEDLINE | ID: mdl-28732655

ABSTRACT

OBJECTIVE: Assess compliance with the IDF recommendations for patients with Diabetes Type2 (DM2), and its variability, by groups of doctors and nurses who provide primary care services in Navarre (Spain). MATERIALS AND METHODOLOGIES: A cross-sectional study of a population of 462,568 inhabitants, aged ≥18 years in 2013, attended by 381 units of doctor/nurse (quota). Clinical data were collected retrospectively through electronic records. Using cluster analysis, we identified two groups of units according to the score for each indicator. We calculated the Odds Ratio, adjusted for age sex, BMI, socioeconomic status and smoking, for complying with each recommendation whether a patient was treated by one of the quota from the highest score to the lowest. 30,312 patients with DM2 were identified: prevalence: 6.39%; coefficient of variation between UDN: 22.8%; biggest cluster 7.7% and smallest 5.3%; OR=1.54 (1.50-1.58). The HbA1c control at ≤8% was 82.8% (82.2-83.3) and >9% was 7.6% (7.3-8.0), with OR 1.79 (1.69-1.89) and 2.62 (2.36-2.91) respectively. Control of BP and LDL-C show significant differences between the clusters. CONCLUSIONS: An important variability was identified according to the doctor treating patients. The average HbA1c control is acceptable being limited in BP and LDL-C.


Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 2/drug therapy , Guideline Adherence/standards , Hypoglycemic Agents/therapeutic use , Practice Guidelines as Topic/standards , Practice Patterns, Physicians'/standards , Primary Health Care/standards , Adolescent , Adult , Anticholesteremic Agents/therapeutic use , Antihypertensive Agents/therapeutic use , Biomarkers/blood , Blood Glucose/metabolism , Blood Pressure/drug effects , Cholesterol, LDL/blood , Cluster Analysis , Cross-Sectional Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/epidemiology , Electronic Health Records , Female , Glycated Hemoglobin/metabolism , Guideline Adherence/trends , Humans , Logistic Models , Male , Middle Aged , Odds Ratio , Practice Patterns, Physicians'/trends , Prevalence , Primary Health Care/trends , Retrospective Studies , Risk Reduction Behavior , Spain/epidemiology , Time Factors , Young Adult
7.
Obes Res Clin Pract ; 9(5): 435-47, 2015.
Article in English | MEDLINE | ID: mdl-25979684

ABSTRACT

BACKGROUND: Overweight and obesity are major causes of comorbidities which can lead to further morbidity and mortality. The main objective of the present study was to estimate the comorbidity associated with obesity in 40,010 patients attending Primary Health Care Centres in Navarra. METHODS: It is a descriptive cross-sectional study. The association of overweight and obesity in different diseases was studied. Odds ratios (OR) adjusted for age and sex were calculated by unconditional logistic regression, using as reference patients with body mass index (BMI) lower than 25 kg/m(2). RESULTS: Increasing BMI is associated with glucose intolerance (OR: 1.07; 95% CI: 1.06-1.08), dyslipidemia (OR: 1.04; 95% CI: 1.03-1.04), hypertension (OR: 1.12; 95% CI: 1.12-1.13), type 2 diabetes (OR: 1.11; 95% CI: 1.10-1.11), kidney failure (OR: 1.04; 95% CI: 1.03-1.05), and osteoarthritis (OR: 1.06; 95% CI: 1.05-1.06). Moreover, all the degrees of obesity are associated with asthma (OR type I obesity: 1.33; OR type II obesity: 1.69; OR type III obesity: 1.75), heart failure (OR type I obesity: 1.68; OR type II obesity: 2.78; OR type III obesity: 4.35), and severe mental disorders (OR type I obesity: 2.02; OR type II obesity: 2.33; OR type III obesity: 2.50). Type II and morbid obesity are associated with chronic obstructive pulmonary disease and depression. CONCLUSION: Our study showed a positive association of the overweight and obesity with glucose intolerance, dyslipidemia, type 2 diabetes, hypertension, osteoarthritis, and kidney failure. An interesting point is the association of higher levels of BMI with depression.


Subject(s)
Body Mass Index , Comorbidity , Obesity/complications , Cross-Sectional Studies , Humans , Logistic Models , Odds Ratio , Risk Factors , Spain
8.
Hormones (Athens) ; 14(2): 280-5, 2015.
Article in English | MEDLINE | ID: mdl-25553761

ABSTRACT

OBJECTIVE: In the last few years a number of studies have found that metformin has a thyrotropin (TSH)-lowering effect in patients with type 2 diabetes (DM2) and that this effect disappears after discontinuation of the drug. Initial studies were carried out in hypothyroid patients on levothyroxine (LT4) treatment. However, this effect was observed only when serum TSH levels were elevated. The aim of this study was to assess the effect of metformin treatment on serum TSH levels in euthyroid DM2 patients. DESIGN: A retrospective study was conducted in seven primary health care centers in Spain. The study included 278 DM2 patients (110 females). Serum TSH level was tested before and one year after the onset of metformin treatment. We compared both TSH levels by paired t-tests. The sample was divided into four hierarchical clusters (C1 to C4), according to the Euclidean distance of the initial TSH level. No patient received LT4 treatment. RESULTS: Pre-metformin serum TSH level (2.00 ± 0.76 mU/L) was statistically significantly lower than post-metformin level (2.20 ± 0.87 mU/L; P <0.001). Interestingly, this trend was observed only in clusters 1 and 2 (those with lower baseline TSH levels), whereas the trend was lost in clusters 3 and 4. The difference between pre- and post-metformin TSH levels follows a mathematical model. According to this model, the TSH threshold point level is 3.00 mU/L. CONCLUSION: Metformin seems to induce a "buffer effect" on TSH secretion in euthyroid diabetic individuals. Hence, our study found an unreported TSH behavior after metformin treatment.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use , Thyrotropin/blood , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Retrospective Studies
9.
Clin Endocrinol (Oxf) ; 79(6): 874-81, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23550997

ABSTRACT

OBJECTIVE: Some evidence suggests that high serum TSH levels are associated with an adverse lipid profile, but this association is not clear when plasma TSH is within the reference range. Nevertheless, these studies have never been conducted in Spain, a country with a strong adherence to the Mediterranean diet. The study aim was to analyse the association between blood TSH levels and circulating lipids in a large Spanish population and set up a TSH reference range in different age, gender and Body Mass Index (BMI) subpopulations from our cohort. DESIGN: Cross-sectional study on 20 783 subjects. PATIENTS: We analysed circulating levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and triglycerides (TG) and compared them with TSH serum levels. Discriminant function analysis was used to determine the TSH cut-off level from where hyperlipidaemia developed. RESULTS: In individuals free of thyroid dysfunction, the mean and the 95% TSH (mU/l) reference limits were 2·20 and 0·72-4·43, respectively. We observed a sex-related difference in TSH concentration (men, 2·07 and 0·72-4·29; women, 2·29 and 0·72-4·49; P < 0·01). We also observed a weight-related difference in TSH concentration (BMI < 30 kg/m(2) , 2·16 and 0·72-4·39; BMI ≥ 30 kg/m(2) , 2·28 and 0·71-4·47; P < 0·01). TSH was positively associated with TC, TG and LDLc levels and negatively with HDLc. CONCLUSION: We found an association between TSH and lipids in that as TSH increased, the lipid profile became less favourable, even within the normal range. Additionally, TSH reference ranges varied according to gender, age and BMI.


Subject(s)
Lipids/blood , Thyrotropin/blood , Adult , Aged , Aged, 80 and over , Cholesterol/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cross-Sectional Studies , Dyslipidemias/blood , Dyslipidemias/etiology , Female , Humans , Hypothyroidism/blood , Hypothyroidism/complications , Male , Middle Aged , Reference Values , Spain , Thyroxine/blood , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...